|
2. Etiologie
|
|
|
Research finds talc doesn’t cause cancer; juries disagree [STAT]
|
|
|
|
|
|
In
the case set to begin Monday in St. Louis, lawyers for Deborah
Giannecchini of Modesto, Calif., say she was diagnosed with ovarian
cancer in 2012 after years of talcum use. Her lawsuit accuses the
company of “negligent conduct” in making and marketing its talc.
|
|
|
|
|
|
|
Your bra could kill you – and other breast cancer myths busted [The Guardian]
|
|
|
|
|
|
A
diagnosis of breast cancer can be frightening, and many of the known
risk factors – genetics, ageing, being a woman – are beyond our control.
That is why myths are attractive. They sell us the idea that there is
something simple we can do to protect ourselves from cancer. We look at
three of the most common myths.
|
|
|
|
|
|
|
3.2 Prévention - Obésité
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
|
5.12 Immunothérapies
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
|
|
|
Kite’s groundbreaking CAR-T hits key study goal, heads to the FDA [EndPoints]
|
|
|
|
|
|
The
biotech says that 62 patients in their study suffering from several
types of NHL who completed at least three months of treatment
demonstrated a combined complete response rate of 39%, down slightly
from the Phase I data. And six-month data, which may be critical in
winning regulators over, is on its way.
|
|
|
|
|
|
|
|
5.12.3 Immunothérapies-combinaisons
|
|
|
|
5.2 Pharma
|
|
|
Pfizer Says They Won’t Break Up [In the Pipeline]
|
|
|
|
|
|
But
if you read the Pfizer statement as referring to 20 new drugs, then no.
They’re certainly not the only company that does this; inflation of
this sort happens all the time. But it’s worth keeping in mind next time
you see a reference to some such figure.
|
|
|
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
Adaptimmune, MD Anderson do I/O deal in T-cell receptors [FierceBiotech]
|
|
|
|
|
|
The
financial terms weren’t disclosed for the multi-year deal, but the
teams will collaborate in areas including targeting MAGE-A10, as well as
MAGE-A4 is cancers including bladder, lung, ovarian, head and neck,
melanoma, esophageal and gastric. The partners will also research new
TCR therapies in breast cancer.
|
|
|
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
5.3 Traitements - FDA, EMA,...
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
5.9.1 ASTRO
|
|
|
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.1 Observation
|
|
|
|
6.6 Publications
|
|
|
Error in one line of code sinks cancer study [Retraction Watch]
|
|
|
|
|
|
Sarah
Darby, last author of the now-retracted paper from the University of
Oxford, UK, told Retraction Watch that the mistake was made by a
doctoral student. When the error was realized, Darby said, she contacted
the Journal of Clinical Oncology (JCO), explained the issue, and asked
whether they would prefer a retraction or a correction. JCO wanted a
retraction, and she complied.
|
|
|
|
|
|